Počet záznamů: 1
Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
- 1.BURDA, P.; HLAVACKOVA, A.; POLIVKOVA, V.; CURIK, N.; LAZNICKA, A.; KRIZKOVA, J.; SUTTNAR, J.; KLENER, P.; MACHOVA POLAKOVA, K.G Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Molecular metabolism. 2024, vol. 88, no. October, art. no. 102016. ISSN 2212-8778. SJR: 3.235, rok: 2024; Cite Score: 14.700, rok: 2024; IF: 6.6, rok: 2024.
Rok vydání Rok metriky IF JCR Q (best) SJR SJR Q (best) CiteScore AIS 1. decil 2024 2024 6.6 Q1 3.235 Q1 14.7 2.675
Počet záznamů: 1